Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States that launched the world’s preeminent cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has entered a strategic partnership with Endocanna Health, Inc., (“Endocanna”) a research and development biotechnology company specializing in endocannabinioid DNA testing and personalization.
Kannaway® and Endocanna will collaborate on the development and distribution of endocannabinoid DNA test products. Under the terms of the agreement, Endocanna will manufacture its patent-pending Endocannabinoid DNA Test Kits (the “Kits”) and license its proprietary DNA technology to Kannaway®. The Kits, designed to provide consumers with personalized data about how cannabidiol (CBD) and other cannabinoids may interact with their body’s regulatory system, will be co-branded and sold exclusively through Kannaway®’s network of brand ambassadors. As part of the agreement, Kannaway® will have the opportunity to incorporate Endocanna’s genetically-aligned formulations into Kannaway’s products.
“Our goal, in addition to offering high-quality hemp-derived CBD products, is to provide our customers with education on which CBD products may work best for them,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “This partnership creates an opportunity for us to do this in an initial hyper-personalized way and help consumers learn how to incorporate CBD into their everyday lives. We are very excited about our first steps in this endeavor with Endocanna, but we also appreciate the growth potential of this partnership with the eventual goal of creating personalized dietary supplement products to fit one’s genetic typing and internal body chemistry. We look forward to creating a long-lasting relationship with Endocanna and improving results for a diverse population, such as we have here in the United States.”
Endocanna is a California-based research and development biotechnology company specializing in genetic testing using DNA to offer a more personalized experience with CBD and other cannabinoids. Endocanna proprietary technology, developed by a team of highly trained specialists and scientists with access to the latest medical research. This technology allows the company to provide consumers with science-backed cannabis product suggestions based on their specific DNA.
“Our partnership with Kannaway provides an opportunity for us to work with an industry leader in developing the most optimal products while advancing the science around CBD,” said Len May, CEO & Co-Founder of Endocanna Health, Inc. “Using Endocanna Health’s proprietary DNA report, we can personalize and provide a cannabinoid wellness protocol tailored to an individual’s needs.”